Last updated on November 2018

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer

Brief description of study

The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating patients with previously untreated inoperable or metastatic urothelial cancer.

Clinical Study Identifier: NCT03036098

Contact Investigators or Research Sites near you

Start Over

Site 0126

Local Institution
Seongnam-si, Korea, Republic of
  Connect »